Evidence map›Paper›PMID 39422780›Full record

ArticleApplied microbiology and biotechnology2024

Development of an RNA virus-based episomal vector with artificial aptazyme for gene silencing.

Ryo Komorizono, Shima Yoshizumi, Keizo Tomonaga

Abstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ryo KomorizonoLaboratory of RNA Viruses, Department of Virus Research, Institute for Life and Medical Sciences (LiMe), Kyoto University, 53 Kawahara-Cho, Shogo-in, Sakyo, Kyoto, 606-8507, Japan.
Shima YoshizumiLaboratory of RNA Viruses, Department of Virus Research, Institute for Life and Medical Sciences (LiMe), Kyoto University, 53 Kawahara-Cho, Shogo-in, Sakyo, Kyoto, 606-8507, Japan.
Keizo TomonagaLaboratory of RNA Viruses, Department of Virus Research, Institute for Life and Medical Sciences (LiMe), Kyoto University, 53 Kawahara-Cho, Shogo-in, Sakyo, Kyoto, 606-8507, Japan. tomonaga@infront.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0003-0405-7103

Funding

Japan Agency for Medical Research and Development JP23bm1223017Japan Society for the Promotion of Science 22K20759Japan Society for the Promotion of Science JP19K22530Japan Society for the Promotion of Science JP20H05682Japan Society for the Promotion of Science JP21K19909Program for Creating STart-ups from Advanced Research and Technology JPMJST2113
6 · The paper itself

Abstract

RNA virus-based episomal vector (REVec), engineered from Borna disease virus, is an innovative gene delivery tool that enables sustained gene expression in transduced cells. However, the difficulty in controlling gene expression and eliminating vectors has limited the practical use of REVec. In this study, we overcome these shortcomings by inserting artificial aptazymes into the untranslated regions of foreign genes carried in vectors or downstream of the viral phosphoprotein gene, which is essential for vector replication. Non-transmissive REVec carrying GuaM8HDV or the P1-F5 aptazyme showed immediate suppression of gene expression in a guanine or theophylline concentration-dependent manner. Continuous compound administration also markedly reduced the percentage of vector-transduced cells and eventually led to the complete elimination of the vectors from the transduced cells. This new REVec is a safe gene delivery technology that allows fine-tuning of gene expression and could be a useful platform for gene therapy and gene-cell therapy, potentially contributing to the cure of many genetic disorders. KEY POINTS: • We developed a bornavirus vector capable of silencing transgene expression by insertion of aptazyme • Transgene expression was markedly suppressed in a compound concentration-dependent manner • Artificial aptazyme systems allowed complete elimination of the vector from transduced cells.

Indexed as

Gene SilencingGenetic VectorsPlasmidsHumansRNA VirusesTransduction, GeneticTransgenesAptazymeBorna virus vectorGene regulationViral vector

Identifiers

PMID39422780
PMCPMC11489216

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.